Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease

Published:2020-10-01 Issue:10 Volume:5 Page:1182
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Honigberg Michael C.¹,Chang Lee-Shing²,McGuire Darren K.³,Plutzky Jorge⁴,Aroda Vanita R.²,Vaduganathan Muthiah⁴

Affiliation:

1. Cardiology Division, Massachusetts General Hospital, Boston

2. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Boston, Massachusetts

3. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas

4. Division of Cardiovascular Medicine, Brigham and Women’s Hospital Heart and Vascular Center, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2766892/jamacardiology_honigberg_2020_rv_200004_1602688160.41027.pdf

Reference46 articles.

1. Prevalence of and trends in diabetes among adults in the United States, 1988-2012.;Menke;JAMA,2015

2. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.;Gregg;Lancet,2018

3. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial.;Fitchett;Circulation,2019

4. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.;Kristensen;Lancet Diabetes Endocrinol,2019

5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.;Zelniker;Lancet,2019

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide;Frontiers in Molecular Biosciences;2024-09-11

2. Comparison of societal guidance on perioperative management of glucagon-like peptide-1 receptor agonists: implications for clinical practice and future investigations;Canadian Journal of Anesthesia/Journal canadien d'anesthésie;2024-08-26

3. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs;Journal of Clinical Medicine;2024-08-09

4. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23

5. GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for CombatingAlzheimer’s Disease through its Supporting DPP4 Inhibitors: A Review;Current Topics in Medicinal Chemistry;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3